Tarceva Survival Advantage In Pancreatic Cancer Not "Clinically Meaningful," FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency's briefing documents for Tarceva's Oncologic Drugs Advisory Committee review raise concerns about rates of serious adverse events and treatment-related fatalities.
You may also be interested in...
Gemzar Narrow Progression-Free Survival Benefit To Test Oncology Panel's Efficacy Bar
FDA's Oncologic Drugs Advisory Committee will review Lilly's gemcitabine for treatment of advanced ovarian cancer March 13.
Gemzar Narrow Progression-Free Survival Benefit To Test Oncology Panel's Efficacy Bar
FDA's Oncologic Drugs Advisory Committee will review Lilly's gemcitabine for treatment of advanced ovarian cancer March 13.
Tarceva Pancreatic Cancer Survival Benefit Is Small But Clinically Meaningful, Committee Says
Tarceva (erlotinib) survival difference of two weeks to one month, depending on the analysis, is statistically persuasive, FDA’s Oncologic Drugs Advisory Committee says at Sept. 13 meeting.